BackTable / ENT / Contributor

Dr. Dylan Roden
Head and Neck Surgeon
Dr. Dylan Roden is a head and neck cancer surgeon and Chair of Robotic Surgery at Rutgers New Jersey Medical School.
Listen to Dr. Dylan Roden on the BackTable Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Dylan Roden and get practical advice on how to build your practice by listening to the BackTable Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Dylan Roden
Dr. Dylan Roden is a head and neck cancer surgeon at Rutgers New Jersey Medical School with expertise in transoral robotic surgery. He serves as the Chair of Robotic Surgery at University Hospital and works as part of the multidisciplinary head and neck team. In addition to treating patients, Dr. Roden is actively expanding the head and neck cancer clinical trial portfolio at Rutgers. As a reconstructive surgeon, he specializes in microvascular free flap, regional flap, and local flap reconstructions.
Dr. Roden earned both his Doctor of Medicine (MD) and Master of Public Health (MPH) degrees from the Icahn School of Medicine at Mount Sinai in Manhattan. He then completed his surgical training in the Otolaryngology – Head & Neck Surgery residency program at New York University (NYU), where he received multiple research awards. Dr. Roden's particular interest in the care of head and neck cancer patients led him to Philadelphia, where he completed a fellowship in advanced head and neck surgical oncology and microvascular reconstruction at Thomas Jefferson University.
Beyond his clinical work, Dr. Roden is passionate about international surgical education and care. As a member of the American Head & Neck Society (AHNS) Global Outreach Service, he regularly travels around the world to volunteer and provide free surgical care to those in need.
Learn more by visiting Dr. Dylan Roden's practice:
Podcasts Featuring Dr. Dylan Roden
Tumor Board Episode #32
While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
ENT Episode #245
While the standard for adjuvant head and neck cancer treatment hasn't changed since 2004, a new trial using perioperative pembrolizumab is forcing clinicians to rethink their entire workflow, starting with diagnosis. In this episode of the BackTable Podcast, head and neck surgical oncologist Dr. Adam Luginbuhl is joined by colleagues Dr. Dylan Roden and Dr. Ravindra Uppaluri to discuss the implementation and implications of the Keynote-689 trial, which introduced neoadjuvant and adjuvant immunotherapy for locally advanced head and neck cancer.
Get in touch!
We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.










